Aarey Drugs & Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Last Updated: February 12, 2026, 9:41 pm

All Competitor Stocks of Aarey Drugs & Pharmaceuticals Ltd

Last Updated: December 28, 2025, 11:04 am

Below is a detailed analysis of the quarterly data for Aarey Drugs & Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Sales, as of Sep 2025, the value is 84.16 Cr.. The value appears to be declining and may need further review. It has decreased from 102.21 Cr. (Jun 2025) to 84.16 Cr., marking a decrease of 18.05 Cr..
• For Expenses, as of Sep 2025, the value is 81.52 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 100.50 Cr. (Jun 2025) to 81.52 Cr., marking a decrease of 18.98 Cr..
• For Operating Profit, as of Sep 2025, the value is 2.64 Cr.. The value appears strong and on an upward trend. It has increased from 1.71 Cr. (Jun 2025) to 2.64 Cr., marking an increase of 0.93 Cr..
• For OPM %, as of Sep 2025, the value is 3.14%. The value appears strong and on an upward trend. It has increased from 1.67% (Jun 2025) to 3.14%, marking an increase of 1.47%.
• For Other Income, as of Sep 2025, the value is 0.79 Cr.. The value appears to be declining and may need further review. It has decreased from 1.55 Cr. (Jun 2025) to 0.79 Cr., marking a decrease of 0.76 Cr..
• For Interest, as of Sep 2025, the value is 1.26 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.04 Cr. (Jun 2025) to 1.26 Cr., marking an increase of 0.22 Cr..
• For Depreciation, as of Sep 2025, the value is 0.69 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.49 Cr. (Jun 2025) to 0.69 Cr., marking an increase of 0.20 Cr..
• For Profit before tax, as of Sep 2025, the value is 1.48 Cr.. The value appears to be declining and may need further review. It has decreased from 1.73 Cr. (Jun 2025) to 1.48 Cr., marking a decrease of 0.25 Cr..
• For Tax %, as of Sep 2025, the value is 31.08%. The value appears to be increasing, which may not be favorable. It has increased from 20.81% (Jun 2025) to 31.08%, marking an increase of 10.27%.
• For Net Profit, as of Sep 2025, the value is 1.02 Cr.. The value appears to be declining and may need further review. It has decreased from 1.37 Cr. (Jun 2025) to 1.02 Cr., marking a decrease of 0.35 Cr..
• For EPS in Rs, as of Sep 2025, the value is 0.36. The value appears to be declining and may need further review. It has decreased from 0.48 (Jun 2025) to 0.36, marking a decrease of 0.12.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Last Updated: December 15, 2025, 4:21 am

Last Updated: September 5, 2025, 2:01 pm

Last Updated: December 4, 2025, 2:15 am

Below is a detailed analysis of the balance sheet data for Aarey Drugs & Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 28.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 28.00 Cr..
• For Reserves, as of Sep 2025, the value is 120.00 Cr.. The value appears strong and on an upward trend. It has increased from 110.00 Cr. (Mar 2025) to 120.00 Cr., marking an increase of 10.00 Cr..
• For Borrowings, as of Sep 2025, the value is 51.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 35.00 Cr. (Mar 2025) to 51.00 Cr., marking an increase of 16.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 94.00 Cr.. The value appears to be improving (decreasing). It has decreased from 117.00 Cr. (Mar 2025) to 94.00 Cr., marking a decrease of 23.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 294.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 291.00 Cr. (Mar 2025) to 294.00 Cr., marking an increase of 3.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 25.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2025) to 25.00 Cr., marking an increase of 9.00 Cr..
• For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
• For Investments, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
• For Other Assets, as of Sep 2025, the value is 267.00 Cr.. The value appears to be declining and may need further review. It has decreased from 272.00 Cr. (Mar 2025) to 267.00 Cr., marking a decrease of 5.00 Cr..
• For Total Assets, as of Sep 2025, the value is 294.00 Cr.. The value appears strong and on an upward trend. It has increased from 291.00 Cr. (Mar 2025) to 294.00 Cr., marking an increase of 3.00 Cr..

Notably, the Reserves (120.00 Cr.) exceed the Borrowings (51.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

After reviewing the key financial ratios for Aarey Drugs & Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 1.42. This value is below the healthy minimum of 5. It has decreased from 1.67 (Mar 24) to 1.42, marking a decrease of 0.25.
• For Diluted EPS (Rs.), as of Mar 25, the value is 1.42. This value is below the healthy minimum of 5. It has decreased from 1.67 (Mar 24) to 1.42, marking a decrease of 0.25.
• For Cash EPS (Rs.), as of Mar 25, the value is 2.10. This value is below the healthy minimum of 3. It has decreased from 2.27 (Mar 24) to 2.10, marking a decrease of 0.17.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.67. It has increased from 47.33 (Mar 24) to 48.67, marking an increase of 1.34.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.67. It has increased from 47.33 (Mar 24) to 48.67, marking an increase of 1.34.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 166.56. It has increased from 141.02 (Mar 24) to 166.56, marking an increase of 25.54.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 4.47. This value is within the healthy range. It has increased from 4.07 (Mar 24) to 4.47, marking an increase of 0.40.
• For PBIT / Share (Rs.), as of Mar 25, the value is 3.78. This value is within the healthy range. It has increased from 3.46 (Mar 24) to 3.78, marking an increase of 0.32.
• For PBT / Share (Rs.), as of Mar 25, the value is 2.14. This value is within the healthy range. It has increased from 1.90 (Mar 24) to 2.14, marking an increase of 0.24.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 1.41. This value is below the healthy minimum of 2. It has decreased from 1.67 (Mar 24) to 1.41, marking a decrease of 0.26.
• For PBDIT Margin (%), as of Mar 25, the value is 2.68. This value is below the healthy minimum of 10. It has decreased from 2.88 (Mar 24) to 2.68, marking a decrease of 0.20.
• For PBIT Margin (%), as of Mar 25, the value is 2.27. This value is below the healthy minimum of 10. It has decreased from 2.45 (Mar 24) to 2.27, marking a decrease of 0.18.
• For PBT Margin (%), as of Mar 25, the value is 1.28. This value is below the healthy minimum of 10. It has decreased from 1.35 (Mar 24) to 1.28, marking a decrease of 0.07.
• For Net Profit Margin (%), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 5. It has decreased from 1.18 (Mar 24) to 0.84, marking a decrease of 0.34.
• For Return on Networth / Equity (%), as of Mar 25, the value is 2.90. This value is below the healthy minimum of 15. It has decreased from 3.52 (Mar 24) to 2.90, marking a decrease of 0.62.
• For Return on Capital Employeed (%), as of Mar 25, the value is 7.61. This value is below the healthy minimum of 10. It has increased from 7.10 (Mar 24) to 7.61, marking an increase of 0.51.
• For Return On Assets (%), as of Mar 25, the value is 1.38. This value is below the healthy minimum of 5. It has decreased from 1.54 (Mar 24) to 1.38, marking a decrease of 0.16.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.25. This value is within the healthy range. It has increased from 0.23 (Mar 24) to 0.25, marking an increase of 0.02.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.60. It has increased from 1.33 (Mar 24) to 1.60, marking an increase of 0.27.
• For Current Ratio (X), as of Mar 25, the value is 1.78. This value is within the healthy range. It has increased from 1.70 (Mar 24) to 1.78, marking an increase of 0.08.
• For Quick Ratio (X), as of Mar 25, the value is 1.48. This value is within the healthy range. It has decreased from 1.49 (Mar 24) to 1.48, marking a decrease of 0.01.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 11.83. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 11.83, marking an increase of 11.83.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 2.73. This value is below the healthy minimum of 3. It has increased from 2.61 (Mar 24) to 2.73, marking an increase of 0.12.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.86. This value is below the healthy minimum of 3. It has decreased from 2.07 (Mar 24) to 1.86, marking a decrease of 0.21.
• For Enterprise Value (Cr.), as of Mar 25, the value is 129.30. It has decreased from 155.10 (Mar 24) to 129.30, marking a decrease of 25.80.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.27, marking a decrease of 0.12.
• For EV / EBITDA (X), as of Mar 25, the value is 10.17. This value is within the healthy range. It has decreased from 13.59 (Mar 24) to 10.17, marking a decrease of 3.42.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 1. It has decreased from 0.31 (Mar 24) to 0.20, marking a decrease of 0.11.
• For Price / BV (X), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 1. It has decreased from 0.94 (Mar 24) to 0.69, marking a decrease of 0.25.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 1. It has decreased from 0.31 (Mar 24) to 0.20, marking a decrease of 0.11.
• For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

About the Company - Qualitative Analysis